Chemotherapy-induced anemia (CIA)
Anemia due to chemotherapy in patients with cancer

PROCRIT® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

In anemic cancer patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
divider
Important dosing and administration information1
Only prescribers enrolled in the ESA APPRISE Oncology Program may prescribe and/or dispense PROCRIT®.

Initiate PROCRIT® in patients on cancer chemotherapy only if the Hb is <10 g/dL, and if there is a minimum of 2 additional months of planned chemotherapy.

Use the lowest dose of PROCRIT® necessary to avoid RBC transfusions.

Recommended Starting Dose
Adults:
  • 150 U/kg SC TIW until completion of a chemotherapy course or
  • 40,000 U SC QW until completion of a chemotherapy course
Pediatric patients (5 to 18 years)
  • 600 U/kg IV QW until completion of a chemotherapy course
Dose Reduction
Reduce dose by 25% if:
  • Hb increases >1 g/dL in any 2-week period or
  • Hb reaches a level needed to avoid RBC transfusion
Withhold dose if Hb exceeds a level needed to avoid RBC transfusion. Reinitiate at a dose 25% below the previous dose when Hb approaches a level where RBC transfusions may be required.

Dose Increase
After the initial 4 weeks of PROCRIT® therapy, if Hb increases by <1 g/dL and remains below 10 g/dL, increase dose to:
  • 300 U/kg TIW in adults or
  • 60,000 U QW in adults
  • 900 U/kg (maximum 60,000 U) QW in children
After 8 weeks of therapy, if there is no response as measured by Hb levels or if RBC transfusions are still required, discontinue PROCRIT®.
divider
Dosing algorithm for adults
  • PROCRIT® is contraindicated in patients with uncontrolled hypertension, pure red cell aplasia (PRCA) that begins after treatment with PROCRIT® or other erythropoietin protein drugs, or severe allergic reactions to PROCRIT®. PROCRIT® from multidose vials contains benzyl alcohol and is contraindicated in neonates, infants, pregnant women, and nursing mothers
*Approximately 10,000–U SC injection based on patient weight of 70 kg.
Approximately 20,000–U SC injection based on patient weight of 70 kg.
divider

References
  1. PROCRIT® (epoetin alfa) Prescribing Information. Janssen Products, LP.
 
Indications and Important Safety Information
EXPAND    Expand ISI
Indications
Expand ISI
Important Safety Information
Expand ISI